Henlius Reports Sustained Growth and Third Consecutive Year of Profitability in 2025

Shanghai Henlius Biotech, Inc. (2696.HK) has released its annual financial results for 2025, demonstrating a strong trajectory of sustained growth. The company reported significant increases in both total revenue and net profits throughout the fiscal year. Notably, 2025 marks the third consecutive year of profitability for the biotech firm since it first reached this milestone in 2023. This performance underscores the success of the company's commercialization efforts and its efficient operational strategies. The consistent financial improvement is expected to bolster investor confidence in the Hong Kong-listed stock. Henlius continues to solidify its position in the competitive biotech sector through its robust product pipeline and market expansion.

Sources:prnewswire.comprnewswire.comnews.futunn.comtipranks.commatrixbcg.comyoutube.comhenlius.comhkexnews.hkprnewswire.commarketscreener.comsimplywall.st